Patents by Inventor Steven E. Cash

Steven E. Cash has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Reagents, methods, and kits for the classification of cancer
    Patent number: 8999657
    Abstract: Reagents, methods, and kits for the classification of cancer that comprise or employ antibodies that bind specific regions of CD43. One method includes contacting tissue with an antibody capable of specifically binding the cytoplasmic tail of CD43, contacting the tissue with an antibody capable of specifically binding the extracellular domain of CD43, and resolving cellular localization of any binding to the tissue with the antibody capable of specifically binding the cytoplasmic tail of CD43 and the antibody capable of specifically binding the extracellular domain of CD43. The binding patterns of the antibodies can be used to characterize cancer as more aggressive or less aggressive and can distinguish small cell lung cancer from non-small cell lung cancer. The cancer may therefore be treated in accordance of the characterization.
    Type: Grant
    Filed: April 2, 2013
    Date of Patent: April 7, 2015
    Assignee: Gundersen Lutheran Health System
    Inventors: Carl S. Shelley, Steven E. Cash, Jeremiah J. Andersen, Qiangwei Fu
  • REAGENTS, METHODS, AND KITS FOR THE CLASSIFICATION OF CANCER
    Publication number: 20130259877
    Abstract: Reagents, methods, and kits for the classification of cancer that comprise or employ antibodies that bind specific regions of CD43. One method includes contacting tissue with an antibody capable of specifically binding the cytoplasmic tail of CD43, contacting the tissue with an antibody capable of specifically binding the extracellular domain of CD43, and resolving cellular localization of any binding to the tissue with the antibody capable of specifically binding the cytoplasmic tail of CD43 and the antibody capable of specifically binding the extracellular domain of CD43. The binding patterns of the antibodies can be used to characterize cancer as more aggressive or less aggressive and can distinguish small cell lung cancer from non-small cell lung cancer. The cancer may therefore be treated in accordance of the characterization.
    Type: Application
    Filed: April 2, 2013
    Publication date: October 3, 2013
    Applicant: Gundersen Lutheran Health System
    Inventors: Carl S. Shelley, Steven E. Cash, Jeremiah J. Andersen, Qiangwei Fu